title: Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14.
authors.affiliation: Molecular Oncology, Washington University, St. Louis, MO, USA. Electronic address: jhsieh@wustl.edu.
authors.forename: James J
authors.initials: JJ
authors.lastname: Hsieh
authors.affiliation: Novartis Oncology, East Hanover, NJ, USA.
authors.forename: Mahtab
authors.initials: M
authors.lastname: Marker
authors.affiliation: Novartis Oncology, East Hanover, NJ, USA.
authors.forename: David
authors.initials: D
authors.lastname: Chen
mesh_terms: D015415:Biomarkers; D002292:Carcinoma, Renal Cell; D000068338:Everolimus; D023281:Genomics; D006801:Humans; D007211:Indoles; D007680:Kidney Neoplasms; D011758:Pyrroles; D000077210:Sunitinib
chemical_list: D015415:Biomarkers; D007211:Indoles; D011758:Pyrroles; D000068338:Everolimus; D000077210:Sunitinib